Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03703206 · ClinicalTrials.gov registry record · Phase 3

The Analgesic Efficacy of Protocol for Primary Total Knee Arthroplasty (TKA)

A Phase 3 study, sponsored by University of Pennsylvania.

Completed
Registry status
Phase 3
Development phase
120
Enrollment target

NCT03703206: Completed Phase 3 study, sponsored by University of Pennsylvania.

NCT03703206 is a Phase 3 study that has completed, run by University of Pennsylvania. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03703206, a Phase 3 study, has completed, sponsored by University of Pennsylvania.

COMPLETED
Registry status
Phase 3
Development phase
120 participants
Enrollment target

Study Summary

This is a perspective, randomized, blinded study with a parallel design and an allocation ratio of 1 to 1 for the treatment groups to assess the analgesic efficacy of adding the iPACK (injection between the popliteal artery and the capsule of the knee) in addition to the adductor canal block (ACB) for Total Knee Arthoplasty patients (TKA).

Interventions

  • DRUG ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK)

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2018-07-01
Est. Completion 2021-08-27
Phase Phase 3

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT03703206

The ClinicalTrials.gov registry entry for NCT03703206 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK) is the first listed.

NCT03703206 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03703206 about?

NCT03703206 is a clinical study titled "The Analgesic Efficacy of Protocol for Primary Total Knee Arthroplasty (TKA)". This is a perspective, randomized, blinded study with a parallel design and an allocation ratio of 1 to 1 for the treatment groups to assess the analgesic efficacy of adding the iPACK (injection between the popliteal artery and the capsule of the knee) in addition to the adductor canal block (ACB) f...

What is the current status of trial NCT03703206?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2018-07-01. Estimated completion is 2021-08-27.

What interventions are being tested in trial NCT03703206?

The interventions under investigation include: ultrasound guided injection of local anesthetic between the popliteal artery and the capsule of the knee (iPACK) (DRUG).

Who is sponsoring clinical trial NCT03703206?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.